Stratec with clear analyst consensus, shares on the SDAX radar
24.06.2026 - 10:14:36 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 10:13.
Stratec (DE000STRA555) remains a niche diagnostics equipment provider with a relatively tight analyst coverage on Xetra. The stock is a member of the SDAX, which keeps it on the radar of German small and mid-cap investors according to Deutsche Börse.
What recent analyst data shows
On MarketScreener, Stratec is followed by a small group of analysts, with most ratings clustered in the Hold to Buy range and an average price target that implies only a moderate upside from recent levels as of late June 2026. MarketScreener’s consensus overview summarizes the distribution.
The consensus data there indicates that only a handful of brokers actively update their models, a typical pattern for SDAX constituents where coverage is often concentrated on domestic houses. The implied upside in the consensus target reflects expectations for steady, but not explosive, earnings growth.
Valuation and peer comparison
Compared with larger European diagnostics and medtech peers such as Siemens Healthineers and Sartorius, Stratec trades in a lower liquidity segment on Xetra but broadly within the sector’s valuation corridor on earnings multiples, according to recent figures compiled by Finanztreff. Finanztreff’s stock profile lists current valuation ratios and index membership.
Sector-wide, European diagnostics groups have faced a normalization after the pandemic testing boom, which has translated into more cautious top-line assumptions. That pattern is visible in the relatively measured price targets on Stratec compared with high-growth biotech names, but also in the focus on recurring consumables revenues and installed base expansion in analyst notes.
All news and analysis on the Stratec shares
Current reports, price data and background on Stratec in the SDAX can be found in the dedicated topic section on ad-hoc-news.de and on the company’s investor relations site.
How Stratec earns its money
Stratec develops and manufactures automated analyzer systems and related consumables for in-vitro diagnostics and life science applications, typically as an original equipment manufacturer for larger diagnostics groups. Its platforms underpin blood testing, molecular diagnostics and immunoassay workflows in clinical laboratories worldwide.
Where the stock trades now
The Stratec shares (DE000STRA555) trade on Xetra as an SDAX constituent; around mid-morning on 2026-06-24 they changed hands at roughly mid-double-digit euros, based on indicative data from Deutsche Börse.
Key data on the Stratec shares
- Company: Stratec SE
- ISIN: DE000STRA555
- WKN: STRA55
- Ticker: SBS
- Trading venue: Xetra
- Price (as of 2026-06-24, 10:13): mid-double-digit euro area
- Market cap: low three-digit million euro range (as of 2026-06-24)
- Sector / industry: Health care equipment & supplies / diagnostics
- Index membership: SDAX
- Next earnings date: not officially scheduled
This article is for information purposes only and does not constitute investment advice, investment recommendations or an offer or solicitation to buy or sell any financial instruments. Investors should conduct their own research and, where appropriate, seek professional advice before making investment decisions.
